Snowball logo
logo
NTRA_logo

Natera, Inc

NTRA โ€ข NASDAQ
$312.575-$3.385ย  (1.07%)
Estimate
EPS
-1.96
Beta
1.514
Growth
Revenue, YoY
37.71%
Net income, YoY
33.65%
FCF, YoY
-173.96%
Forecast
EPS (FWD)
-0.35
About the company
Ticker
NTRA
ISIN
US6323071042
Country
United States of America
Sector (GICS)
Healthcare
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar

Frequently asked questions

What sector does Natera, Inc (NTRA) operate in?

Natera, Inc belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is Natera, Inc (NTRA) current stock price?

As of the latest data, Natera, Inc stock price is $312.58, with a previous close of $315.96. Natera, Inc lost -$3.39 in the last trading session, representing a -1.07% loss.

What is Natera, Inc (NTRA) current market capitalization?

Natera, Inc market cap is approximately 45.06 billion.

What is Natera, Inc (NTRA) Earnings Per Share (EPS)?

The trailing EPS is -$1.96, and the forward EPS is -$0.35.

What is Natera, Inc (NTRA) EBITDA?

Natera, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -66.34 million.

Does Natera, Inc (NTRA) pay dividends?

No. Natera, Inc does not pay a dividend.

How did Natera, Inc (NTRA) perform in its most recent earnings report?

In the last report (June 30, 2026), Natera, Inc posted an EPS surprise of 0% and a revenue surprise of 13.83%.

What is Natera, Inc (NTRA) beta (volatility) score?

Natera, Inc has a beta of 1.514, suggesting it is more volatile than the market.